Vertiv NYSE: VRT) stock is moving lower Wednesday following the company's recent quarterly report. The company's share price was down 2.5% as of 3:30 p.m. ET despite the S&P 500 being up 0.8% at the same point in the session and the Nasdaq Composite being up 1.4%. The stock had been off as much as 5% earlier in the day. Vertiv published its first-quarter results before the market opened today and ...
Vertiv NYSE: VRT) stock is moving lower Wednesday following the company's recent quarterly report. The company's share price was down 2.5% as of 3:30 p.m. ET despite the S&P 500 being up 0.8% at the same point in the session and the Nasdaq Composite being up 1.4%. The stock had been off as much as 5% earlier in the day. Vertiv published its first-quarter results before the market opened today and delivered better-than-expected earnings. Despite the profit beat, the company's share price is moving lower today. Image source: Getty Images. Continue reading
Microsoft released an emergency patch for its ASP.NET Core to fix a high-severity vulnerability that allows unauthenticated attackers to gain SYSTEM privileges on devices that use the Web development framework to run Linux or macOS apps. The software maker said Tuesday evening that the vulnerability, tracked as CVE-2026-40372, affects versions 10.0.0 through 10.0.6 of the Microsoft.AspNetCore.Data...
Microsoft released an emergency patch for its ASP.NET Core to fix a high-severity vulnerability that allows unauthenticated attackers to gain SYSTEM privileges on devices that use the Web development framework to run Linux or macOS apps. The software maker said Tuesday evening that the vulnerability, tracked as CVE-2026-40372, affects versions 10.0.0 through 10.0.6 of the Microsoft.AspNetCore.DataProtection NuGet, a package that’s part of the framework. The critical flaw stems from a faulty verification of cryptographic signatures. It can be exploited to allow unauthenticated attackers to forge authentication payloads during the HMAC validation process, which is used to verify the integrity and authenticity of data exchanged between a client and a server. Beware: forged credentials survive patching During the time users ran a vulnerable version of the package, they were left open to an attack that would allow unauthenticated people to gain sensitive SYSTEM privileges that would allow full compromise of the underlying machine. Even after the vulnerability is patched, devices may still be compromised if authentication credentials created by a threat actor aren’t purged. Read full article Comments
Earnings Call Insights: Amneal Pharmaceuticals (AMRX) Q1 2026 Management View "Today is a defining moment for Amneal." (Co-Founder, Co-CEO, President & Director Chirag Patel) "This morning, we announced that Amneal agrees to acquire Kashiv BioSciences, creating a fully integrated global biosimilars leader and positioning Amneal to become the #1 affordable medicines company in the United States." (...
Earnings Call Insights: Amneal Pharmaceuticals (AMRX) Q1 2026 Management View "Today is a defining moment for Amneal." (Co-Founder, Co-CEO, President & Director Chirag Patel) "This morning, we announced that Amneal agrees to acquire Kashiv BioSciences, creating a fully integrated global biosimilars leader and positioning Amneal to become the #1 affordable medicines company in the United States." (Co-Founder, Co-CEO, President & Director Patel) "Q1 marked another consecutive quarter of strong top and bottom line growth with revenue up 4%, adjusted EBITDA up 19% and EPS up 29%." (Co-Founder, Co-CEO, President & Director Patel) "Our strong start of the year, combined with growth of existing and new products, gives us confidence to raise our stand-alone guidance for 2026." (Co-Founder, Co-CEO, President & Director Patel) "The upfront value of $750 million is a 50-50 mix of cash and equity." (Executive VP & CFO Anastasios Konidaris) "The equity portion translates to approximately $29 million of Amneal shares, representing 8% equity dilution." (Executive VP & CFO Konidaris) "We expect $400 million to $500 million in cumulative financial synergies over time." (Executive VP & CFO Konidaris) "First, we're now capturing full economics from partnered assets by eliminating milestones and profit-sharing obligations that existed as part of prior licensing deals." (Executive VP & CFO Konidaris) "Kashiv is a biologics platform built over 12 years with more than $900 million invested, 600-plus employees and 4 R&D and manufacturing sites." (Co-Founder, Co-CEO & Director Chintu Patel) "Drug substance capacity is expected to scale from 26,000 liter in 2026 to 75,000 liter by 2028." (Co-Founder, Co-CEO & Director Patel) Outlook "On a combined basis, including Kashiv, our 2026 view remains largely unchanged aside from a small impact to cash flow related to near-term transaction and integration costs." (Executive VP & CFO Konidaris) "Importantly, we're maintaining the higher adjusted EBIT...
quantic69/iStock via Getty Images The last time I spoke about Kyverna Therapeutics ( KYTX ), it was with a Seeking Alpha article entitled " Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing ." With respect to this article, I mentioned that this company had achieved the primary endpoint of its single-arm registrational phase 2 KYSA-8 study using miv-ce...
quantic69/iStock via Getty Images The last time I spoke about Kyverna Therapeutics ( KYTX ), it was with a Seeking Alpha article entitled " Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing ." With respect to this article, I mentioned that this company had achieved the primary endpoint of its single-arm registrational phase 2 KYSA-8 study using miv-cel for the treatment of patients with stiff person syndrome [SPS]. Specifically, this therapy allowed it to meet the primary endpoint of the change from baseline in the timed 25-foot walk [T25FW] at 16 weeks in a statistically significant manner. At that time, I had a "Strong Buy" rating on this stock because of this feat that was achieved. It has also previously released positive data from its phase 2 portion of its phase 2/3 KYSA-6 registrational study using miv-cel for the treatment of patients with Generalized Myasthenia Gravis [gMG]. This was an interim analysis of 6 patients with gMG who were given miv-cel. It was noted that 100% [6 out of 6] of patients who took this therapy were able to achieve clinically meaningful reductions in MG-ADL and QMG scores from baseline regardless of prior biologic experience. Today, I'm going to maintain a "Strong Buy" rating on this stock. There are several reasons why I believe such a rating should remain. The first of which is because the company just released a late-breaking oral presentation of data from the KYSA-8 trial. The point is that the company is well equipped to file its Biologics License Application [BLA] of miv-cel for the treatment of patients with stiff person syndrome [SPS] in the 1st half of 2026. This sets the ability for its autologous CD-19 CAR T-cell therapy, miv-cel, to become the first treatment option for patients with SPS. The second reason is because the company also presented long-term data showing that miv-cel was able to achieve deepening of responses in the ongoing KYSA-6 trial out to 52 weeks. I will be ...
Andrew Harnik/Getty Images News Kevin Warsh, U.S. President Donald Trump’s nominee for Federal Reserve chair, told lawmakers this week he wants to change how the central bank measures inflation, though economists warn the shift could complicate his approach to monetary policy. During his Senate confirmation hearing Tuesday, Warsh said he prefers “trimmed average” inflation measures over the Fed’s ...
Andrew Harnik/Getty Images News Kevin Warsh, U.S. President Donald Trump’s nominee for Federal Reserve chair, told lawmakers this week he wants to change how the central bank measures inflation, though economists warn the shift could complicate his approach to monetary policy. During his Senate confirmation hearing Tuesday, Warsh said he prefers “trimmed average” inflation measures over the Fed’s traditional core price index for personal consumption expenditures (PCE). The trimmed approach removes extreme price movements to reveal underlying inflation trends. “What I’m most interested in is: What’s the underlying inflation rate?” Warsh said. “We take out all of the tail-risks, all of the one-off items, and we ask ourselves whether the generalized change in prices is having second-order effects on the economy.” Bank of America economist Aditya Bhave reportedly noted that while trimmed measures currently show softer inflation—a 2.3% mean compared with core PCE at 3%—the strategy carries risks. Bhave warned that food and energy prices, currently excluded from core PCE, could still influence trimmed readings during volatile periods. Historical data shows trimmed-median inflation exceeded core PCE in 2019 and 2020, which would have encouraged a more hawkish Fed stance. “To preserve Fed credibility and avoid optics of cherry picking, Warsh will need to stick with his preferred metrics even when they are outpacing the core,” Bhave said, CNBC reported. Bank of America More on the U.S. Economy and Markets Dow Jones And U.S. Stock Market Outlook - Nasdaq Breaks A New Record After Ceasefire Extension Not All 'Safe' Assets Are Safe: Rethinking Treasury ETFs In A High-Deficit World Retail Sales Spike, Here's What It Means For Markets Market breadth is driving the current rally in stocks – strategist Stock selection is the way to go as markets experience continued volatility - Raymond James’s Larry Adam